Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the next ... Oct 14
Published in the European Journal of Pharmacology, the scientific review explores how immune regulation, regenerative medicine and emerging technologies could shape the future of hair-... Sep 24
Immuneel Therapeutics Pvt. Ltd., an Indian company pioneering cell and gene therapy, has entered into a strategic Memorandum of Understanding (MoU) with Tata Memorial Centre (... Jul 16
The first globally approved synthetic cannabidiol oral solution 150mg/ml prescription by psychiatrists only for the management of mild to moderate anxiety disorders, used in ... Jul 15
Gulf Medical University’s Ajman-to-Poland route enters its tenth year as the program that began with 27 students prepares its next batch.... Jun 03
Cancer therapy has always been a contest between persistence and innovation. With each discovery, the balance shifts slightly in favor of hope... Feb 25
Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself or the body. However, a new ... Feb 20
... Feb 18
In a major step towards transforming the treatment landscape for high burden diseases such as cancers and autoimmune disorders, Immuneel Therapeutics Private Limited and Manas ... Feb 10
When cancer learns to fight back, science, it seems, is learning to fight smarter, turning survival tricks into targets and resistance into revelation.... Jan 02
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ... Oct 16
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of its Tumor-Associated Antigen ... Oct 15
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint. In ACHIEVE-5, orforglipron ... Oct 15
Everest Medicines today announced a strategic equity investment in I-Mab, under which Everest will invest US$30.9 million in cash.... Aug 05
HighTide Therapeutics, a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases.... Apr 25
The QIDP designation by the United States Food and Drug Administration (US FDA) underscores the urgent global need for safer polymyxin-based therapies... Apr 17
The FDA has granted APC-148 a Qualified Infectious Disease Product designation, giving the product regulatory priority review and access to fast track and rolling ... Mar 27
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies and could be game-changing for patients ... Feb 25
From its humble beginning in Bhubaneswar to its recognition on the global stage, the startup embodies the spirit of Indias biotechnology revolution.... Jan 28
FMD differs from traditional fasting in that it allows for a controlled intake of certain nutrients, providing the body with essential vitamins, minerals, and other ... Aug 17
STP125G is a single-stranded siRNA therapeutics targeting ApoC3 mRNA, based on Sirnaomics proprietary GalAheadTM mxRNA technology.... Jul 24
As the ZM008-001 clinical trial progresses, the medical community eagerly awaits the results, which could lead the way for a new era in cancer ... Jun 13
here is a clear demand for a mid-sized, agile and responsive CRO with an in-house regulatory affairs team and a proven track record ... Jun 04
Continued research and development in this area are essential to realizing the full potential of RNA-based vaccines in advancing public health and disease prevention ... Apr 17
-Advertisements-
-23-300x250.png)
.jpeg)
Friday, October 30, 2026
.jpg)
.jpg)
.jpg)
.jpg)
.png)
.jpeg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
